bioRxivCell BiologyPreprint
Development of a PROTAC Targeting Chk1
Abstract
A series of Chk1 degraders were designed and synthesized. The degraders were developed through the conjugation of a promiscuous kinase binder and thalidomide. One of the degraders PROTAC-2 was able to decrease Chk1 levels in a concentration-dependent manner in A375 cells. The developed probes can be useful for the development of selective and more potent Chk1 degraders.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Efficiency and localisation of AURKA degradation by PROTACs is modulated by deubiquitinases UCHL5 and target-selective OTUD6A
Annabel Cardno, Karen Roberts, Catherine Lindon·bioRxiv·Apr 23, 2025
- A cell-based degrader assessment platform facilitates discovery of functional NUDT5 PROTACs
Seher Alam, Maria Joao Almeida A Silva Pires, … Mikael Altun·bioRxiv·Jun 13, 2025
- Chemically Induced Degradation of Native Proteins by Direct Recruitment to the 26S Proteasome
Madeline Balzarini, Weijun Gui, … Thomas J. Kodadek·bioRxiv·Jul 19, 2023
- Chemoproteomics-Enabled Discovery of a Covalent Molecular Glue Degrader Targeting NF-κB
E. A. King, Y. Cho, … D. K. Nomura·bioRxiv·May 18, 2022
- Harnessing PROTAC technology to combat stress hormone receptor activation
Mahshid Gazorpak, Karina M. Hugentobler, … Katharina Gapp·Nature CommunicationsPeer-reviewed·Dec 9, 2023
- A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
B. Tong, J. N. Spradlin, … D. K. Nomura·bioRxiv·Apr 2, 2020